Phase One Development of Huygens™ Smart Catheter & Proteus™ Robotic Platform Completed

FOR IMMEDIATE RELEASE

DATELINE: March 14, 2022 Lake Forest California

Announced today by Robert Pryke, PFD Capital Partners, LLC Director and PFD Management Opportunity Fund 3001, LLC fund manager that Neuro-KInesis, Corp. (NKC), a medical technology company focused on developing next-generation surgical tools that utilize advanced biosensor technologies combined with cutting-edge AI and robotics, have completed the Phase One development for their new Huygens™ Smart Catheter and Proteus™ Robotic Arm platform. In achieving this milestone, NKC has successfully completed six strategic goals towards its efforts to bring its patented EP Catheter Mapping and Guidance Technology to the Electrophysiology marketplace.

GOAL ONE: Funding Round of $2.5 Million

Neuro-Kinesis, Corp. (NKC) has completed its initial investment transaction, with the rst tranche commitment of $2.5MM which ensures funding for the development, fabrication, and animal study of the Huygens-Proteus robotic surgical platform.

Proteus™ Catheter Handle with the Lorentz Active Steerable Sheath™

GOAL TWO: Huygens™ Smart Catheter and the Proteus™ Smart Robot Platform Phase One Development Complete

NKC has completed its Phase 1 development path for the Huygens™ Smart  Catheter and the Proteus™ Robotic Arm platform, and will be commencing its analytical phase in April 2022.

The Huygens™ Smart Catheter

The Huygen’s™ Catheter provides a major advancement in catheter-based mapping abilities for the Electrophysiology (EP) field. EP physicians and surgeons depend on the ability of a mapping catheter to provide the roadmap of the patient’s internal cardio environment in order to determine where issues related to electric signaling are causing irregularities in the heart’s rhythm. By being able to accurately map the heart tissues, an EPO surgeon is able to determine the necessary ablation points required to restore regular sinus rhythm, and therefore cardio-health to the patient. Current technology though has several limitations chief of which is its limited ability to detect the desired electrical signals from the undesired signals and noise in order to create a reliable map. The Huygens™ Smart Catheter greatly improves the delity and resolution of capacitance-based mapping systems used by the EP surgeon for clinical assessment and the subsequent guided surgical procedures. The catheter addresses and solves the problems of current mapping catheter limitations by moving all the signal gathering and analog interpretation of heart mapping, from the distal end of the catheter, which is generally inside a machine more than 6-10 feet away from the catheter tip, to an embedded architecture that resides on the catheter tip electrode itself. Through proprietary miniaturization and algorithmic process, NKC has been able to create a catheter electrode that can gather relevant electrode biopotential reading at a level 200 times smaller than current technologies, and then correlate and process that analog data and convert it immediately to digital data that is incorruptible, which is then sent back to the surgeons.

The Proteus™ Robotic Guidance System

Proteus™ Robotic Arm

The Proteus™ Robotic Guidance System has taken its two decades of experience
in developing catheter guidance systems and produced the rst portable robotic-assisted catheter guidance system. The Proteus™ provides the EP Surgeon the ability to not only robotically move a catheter in any axis of orientation with a ner degree of control than can be done manually, but also the ability to map and recall

those movements at the push of a button. This allows an EP Surgeon to be able to instantly return to a marked position as well as the ability to execute a pre-programmed point-to-point navigation path with the catheter in three axes of movement; deflection, translation, and rotation, utilizing three independent drive systems to control catheter movement.

GOAL THREE: Animal Study Set for Rambam Hospital, Israel

Rambam Universtiy Hospital Complex in Haifa, Israel

An ISO audit for the company will be completed in April 2022, and NKC  anticipates that will begin its animal study by June 2022 at its on-site clinical laboratory with Dr. Eli Gang MD, and at Rambam Hospital in collaboration with Haifa University, Israel, under the direction of Prof. Lior Gepstein MD, PhD, and Prof. Mahmoud Suleiman MD.

NKC Animal Study Team

Dr. Eli Gang is a Clinical Professor of Medicine at the David Geen School of Medicine at UCLA. He specializes in the diagnosis and treatment of complex arrhythmias and has been a hands-on EP surgeon for more than 30 years. He is an expert in catheter ablation and implantation of pacemakers and automatic de-fibrillators. His research interests have included the development of advanced ECG technologies as well as the development of robotic approaches to ablation in the heart. Dr. Gang has been part of NKC’s smart catheter and robotic catheter guidance systems technology development since its inception and has been a contributor to many of the key breakthroughs the technology has had over its 20-year history.

Professor Lior Gepstein is the Director of the Cardiology Department at Rambam Health Care Campus. He has extensive experience and a research focus on basic and clinical cardiac electrophysiology, stem cell biology, inherited cardiac disorders, and the establishment of novel gene and cell-based strategies for the treatment of dierent cardiac disorders. Prof. Gepstein’s research group was among the pioneers in developing unique cardiomyocyte dierentiation strategies from human embryonic stem cells and human-induced pluripotent stem cells. He was also central to the development of a three-dimensional electroanatomical mapping technique (CRTO system), which became the state-of-the-art method for the treatment of complex cardiac arrhythmias.

Professor Mahmoud Suleiman is a Senior Cardiologist specializing in Clinical Electrophysiology at Rambam Hospital. He has been deeply involved in the academic and research activities of the Cardiology Division. His major research interests are the role of inflamation in acute coronary syndromes, inflammmation, cardiac arrhythmias, and advanced electroanatomical mapping in cardiac arrhythmias. He is a noted lecturer and speaker on a variety of EP issues and has several published articles on various topics. He has twice received the H.N. Neufeld Award for excellent medical research.

GOAL FOUR: Animal Lab Being Established at NKC Facility

NKC is currently establishing its in-house animal lab with all interface support equipment, including EnSite mapping station with the support of Abbott/St. Jude, as well as X-ray and other associated medical systems and devices required to perform the clinical animal trials for the Huygens™ Smart Catheter, and subsequently the integrated Huygens™- Proteus™ robotic platform.

Concept drawing of the new NKC Animal Lab

NKC First Patent Filing

GOAL FIVE: NKC New Patent Applications Filed

Additional patents have been submitted for NKC proprietary technologies in the US and internationally, including Catheter for Cardiac and Renal Nerve Sensing and Mediation (17/468,460), and Optically Coupled Catheter and Method of Using the Same (16/424,202), awards pending.

Dr. Roger Kornberg

GOAL SIX: New Member Added to NKC Board of Directors

NKC is also pleased to announce the addition of Dr. Roger Kornberg PhD to its Board of Directors. Dr. Kornberg is an American biochemist and professor of structural biology at Stanford University School of Medicine, and the recipient of the 2006 Nobel Prize for Chemistry for his studies of Concept Illustration of the NKC Animal Study Lab on the molecular basis of eukaryotic transcription. Prior to joining the faculty at Stanford University School of Medicine, Dr. Kornberg was a postdoctoral research fellow at the Laboratory of Molecular Biology in Cambridge, England. In 1976 he became an Assistant Professor of Biological Chemistry at Harvard Medical School before moving to his current present position at Stanford Medical School in 1978. Dr. Kornberg has served as the Chairman of the Scientic Advisory Boards of many companies including Cocrystal Discovery, Inc,  ChromaDex Corporation, StemRad, Ltd, Oplon Ltd, and Pacic Biosciences. He has also served as a Board Director for OphthaliX Inc., Protalix BioTherapeutics, Can-Fite BioPharma, Ltd, and Teva PharmaceuticalIndustries, Ltd.